Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOXO-305 Drug Interaction Study with CYP Substrates
NCT06215430Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2021
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pirtobrutinib in mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Time Curve From Hour 0 to 24 Hours Post-Dose, Area Under the Concentration-time Curve From Hour 0 to the Last Measurable Concentration at Day 15 and 10 more. Started Jan 2021; status: completed.
02
Drugs
pirtobrutinib
03
Conditions
mantle cell lymphoma (MCL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT06215430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06215430.